中国医药：关于子公司药品通过仿制药一致性评价的公告

Core Viewpoint - China Medical announced that its wholly-owned subsidiary, Tianfang Pharmaceutical, received approval from the National Medical Products Administration for the supplement application of Lincomycin Hydrochloride Injection, which has passed the consistency evaluation of generic drug quality and efficacy [1]. Group 1 - The approval signifies a regulatory milestone for the company, enhancing its product portfolio in the pharmaceutical market [1]. - The drug's successful consistency evaluation indicates that it meets the required standards for quality and efficacy, which is crucial for market competitiveness [1].